[18F]CTT1057 PET/CT在生化复发前列腺癌患者中的显像效能:GuidePath 3期前瞻性多中心研究结果
GuidePath 3期前瞻性多中心研究纳入161例可评估的生化复发前列腺癌患者,其中93.2%为首次生化复发,基线中位PSA为0.4 ng/mL。患者接受[18F]CTT1057 PET/CT与[68Ga]Ga-PSMA-11 PET/CT,以复合真值标准评估,区域水平正确定位率为65.2%–75.0%,患者水平阳性预测值为64.6%–76.5%,两项共同主要终点均达到预设阈值。
要点
- 在首次生化复发且PSA低的患者中,[18F]CTT1057 PET/CT的区域水平CLR为65.2%–75.0%,患者水平PPV为64.6%–76.5%。
- 3位独立读者的两项共同主要终点95%CI下限均超过预设阈值(CLR>50%、PPV>20%)。
- 99%的患者(159–160例)采用影像学真值标准,而非组织病理学。
核心结论
- [18F]CTT1057在主要为首次生化复发且PSA水平低的临床相关队列中,达到预设的区域水平CLR和患者水平PPV阈值。
- [18F]CTT1057是一种用于生化复发检测的准确PSMA靶向PET放射性示踪剂。
研究设计与样本
- GuidePath为前瞻性3期多中心研究(NCT04838613),旨在评估PSMA靶向PET示踪剂[18F]CTT1057检测PSMA阳性病灶的显像效能。
- 入选标准为根治性前列腺切除术后PSA≥0.2 ng/mL,或放疗后PSA较最低点升高≥2 ng/mL。
- 患者接受370 MBq [18F]CTT1057后90分钟(±30分钟)行PET/CT,并接受150 MBq [68Ga]Ga-PSMA-11后50–100分钟行PET/CT。
- [18F]CTT1057图像由3位独立读者在不知晓所有临床信息的条件下评估。
- 共同主要终点为区域水平正确定位率(CLR)和患者水平阳性预测值(PPV),与分层复合真值标准(CTS)比较。
主要发现
- 202例筛选患者中161例可评估疗效,其中93.2%为首次生化复发,96.3%以根治性前列腺切除术为初始确定性治疗。
- 基线中位PSA为0.4 ng/mL(四分位距0.3–0.8 ng/mL)。
- 3位读者中有159–160例患者(99%)采用影像学真值标准。
- 区域水平CLR范围为65.2%–75.0%(95%CI下限53.4%–62.1%),患者水平PPV范围为64.6%–76.5%(95%CI下限51.8%–62.5%)。
- 两项共同主要终点均达到。
关键数值与推荐
- 研究成功标准:3位[18F]CTT1057 PET/CT读者中至少2位的区域水平CLR的95%CI下限须超过50%,患者水平PPV的95%CI下限须超过20%。
- 复合真值标准(CTS)分3级(按优先级):组织病理学(CTS 1级);影像学包括至少1次增强CT和1次[68Ga]Ga-PSMA-11 PET/CT(CTS 2级);放疗后3个月PSA下降≥50%(CTS 3级)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Improved diagnostic accuracy in patients with prostate cancer at first biochemical recurrence (BCR) with low prostate-specific antigen (PSA) levels is needed. This prospective study (GuidePath; NCT04838613) aimed to evaluate the imaging performance of the prostate-specific membrane antigen (PSMA)-targeted PET radiotracer [18F]CTT1057 to detect PSMA-positive lesions in patients diagnosed predominantly at first BCR. Methods: Eligible patients had a PSA of 0.2 ng/mL or greater after radical prostatectomy or an increase in PSA level of at least 2 ng/mL above nadir after radiation therapy. Patients received 370 MBq of [18F]CTT1057 and 150 MBq of [68Ga]Ga-PSMA-11 and underwent PET/CT 90 min (±30 min) and 50-100 after injection, respectively. [18F]CTT1057 images were assessed by 3 independent readers blinded to all clinical information. Coprimary endpoints were region-level correct localization rate (CLR) and patient-level positive predictive value (PPV) of [18F]CTT1057 to detect PSMA-positive lesions and were compared with a hierarchical composite truth standard (CTS). The CTS comprised 3 levels of standard-of-truth procedures (in order of priority): histopathology (CTS level 1); imaging, including at least 1 contrast-enhanced CT scan and 1 [68Ga]Ga-PSMA-11 PET/CT scan (CTS level 2); and a decrease in PSA level of 50% or greater 3 mo after radiation therapy (CTS level 3). For study success, the lower-bound 95% CI had to surpass 50% for region-level CLR and 20% for patient-level PPV for at least 2 of the 3 [18F]CTT1057 PET/CT readers. Results: Of 202 patients screened, 161 were evaluable for efficacy. Among these, 93.2% were experiencing their first BCR, 96.3% had received radical prostatectomy as initial definitive therapy, and baseline median PSA level was 0.4 ng/mL (interquartile range, 0.3-0.8 ng/mL). The imaging standard of truth was used for 159-160 patients (99%) across the 3 readers. Both coprimary endpoints were met. Region-level CLR ranged from 65.2% to 75.0% (lower-bound 95% CI, 53.4%-62.1%), and patient-level PPV ranged from 64.6% to 76.5% (lower-bound 95% CI, 51.8%-62.5%). Conclusion: [18F]CTT1057 met the predefined thresholds for region-level CLR and patient-level PPV in a clinically relevant patient cohort predominantly at first BCR with low PSA levels. [18F]CTT1057 is an accurate PSMA-targeted PET radiotracer for BCR detection.
引用
- Fanti S, Robles Barba JJ, Behr S, et al. Imaging Efficacy of [18F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath-A Phase 3, Prospective Multicenter Study. J Nucl Med. 2025. PMID: 40473464. doi:10.2967/jnumed.124.269266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。